---
title: "Bank of America Securities Keeps Their Hold Rating on Keros Therapeutics (KROS)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/271517136.md"
description: "Bank of America Securities analyst Jason Zemansky has maintained a Hold rating on Keros Therapeutics (KROS) with a price target of $20.00. Zemansky, a 5-star analyst, has an average return of 21.2% and a 61.14% success rate. The consensus on Keros Therapeutics is a Moderate Buy, with an average price target of $21.20."
datetime: "2026-01-05T12:56:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/271517136.md)
  - [en](https://longbridge.com/en/news/271517136.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/271517136.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/271517136.md) | [繁體中文](https://longbridge.com/zh-HK/news/271517136.md)


# Bank of America Securities Keeps Their Hold Rating on Keros Therapeutics (KROS)

Bank of America Securities analyst Jason Zemansky maintained a Hold rating on Keros Therapeutics today and set a price target of $20.00.

### Claim 70% Off TipRanks This Holiday Season

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Zemansky is a 5-star analyst with an average return of 21.2% and a 61.14% success rate. Zemansky covers the Healthcare sector, focusing on stocks such as Kura Oncology, Arcus Biosciences, and Cytokinetics.

Currently, the analyst consensus on Keros Therapeutics is a Moderate Buy with an average price target of $21.20.

## Related News & Research

- [Advantage Energy Ltd. (OTCMKTS:AAVVF) Receives Average Rating of "Moderate Buy" from Analysts](https://longbridge.com/en/news/280981094.md)
- [Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Given Consensus Rating of "Moderate Buy" by Brokerages](https://longbridge.com/en/news/281385107.md)
- [DBS Sticks to Its Buy Rating for Television Broadcasts Limited (0511)](https://longbridge.com/en/news/280928827.md)
- [Oncotelic Therapeutics Delays Annual 10-K Filing](https://longbridge.com/en/news/281283330.md)
- [Tvardi Therapeutics reports larger-than-expected Q4 net loss](https://longbridge.com/en/news/281237072.md)